392,417 Shares in Illumina, Inc. $ILMN Bought by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 392,417 Illumina shares worth approximately $69 million, taking a 0.26% stake. Institutional investors and hedge funds collectively own 89.42% of the company.
• Analyst sentiment remains mixed, with an average “Hold” rating and a $188.40 price target. Price targets range from $160 at Barclays to $230 at JPMorgan.
• Illumina reported quarterly EPS of $1.31, beating estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. Shares opened at $213.24, near the company’s 52-week high of $220.32.

Deutsche Bank AG acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 392,417 shares of the life sciences company's stock, valued at approximately $68,999,000. Deutsche Bank AG owned approximately 0.26% of Illumina at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Plato Investment Management Ltd purchased a new stake in Illumina during the 2nd quarter worth approximately $948,000. Impact Partnership Wealth LLC increased its stake in shares of Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company's stock worth $1,366,000 after buying an additional 7,780 shares during the last quarter. Insight Wealth Strategies LLC acquired a new stake in Illumina in the second quarter valued at $6,062,000. Perigon Wealth Management LLC acquired a new stake in Illumina in the second quarter valued at $1,004,000. Finally, SG Americas Securities LLC boosted its stake in Illumina by 8.0% during the 1st quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company's stock valued at $10,640,000 after acquiring an additional 6,425 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on ILMN. JPMorgan Chase & Co. boosted their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Evercore reaffirmed an "outperform" rating on shares of Illumina in a research report on Monday, July 6th. Sanford C. Bernstein reiterated a "market perform" rating and issued a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. Canaccord Genuity Group boosted their price objective on Illumina from $190.00 to $205.00 and gave the company a "hold" rating in a report on Monday, August 3rd. Finally, Barclays upped their price objective on Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Illumina has an average rating of "Hold" and an average price target of $188.40.

Illumina Stock Up 4.0%

Shares of NASDAQ:ILMN opened at $213.24 on Friday. The stock has a market capitalization of $32.20 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 2.89 and a beta of 1.45. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $220.32. The company's fifty day moving average is $186.84 and its two-hundred day moving average is $151.97. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the previous year, the business posted $1.19 EPS. The company's quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the firm's stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider owned 20,338 shares of the company's stock, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company's stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,416,384 shares of company stock valued at $256,164,151 over the last ninety days. Insiders own 2.90% of the company's stock.

Illumina Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source